by Tori Staniewicz | Jul 20, 2026
Wiggin and Dana attorneys Paul Hughes, Evan Kipperman, Daniela Badiola Spanos, Katherine “Katie” Rubino, Tamia Simonis, and Mark Heaphy authored the “USA – Massachusetts Trends and Developments” chapter for Chambers and Partners’ Doing...
by Siena Mangi | Jul 16, 2026
A small drafting mistake can have major consequences in patent law. That was the lesson from Enanta Pharmaceuticals, Inc. v. Pfizer Inc., where the Federal Circuit held in a precedential opinion that Enanta’s patent could not rely on the filing date of its earlier...
by Siena Mangi | Jul 9, 2026
Since Alice and Mayo came down, Software patents have started to drown. But a SMED’s the new way To keep 101 at bay— And turn that rejection around! Background Under 35 U.S.C. § 101, patent applicants must demonstrate that their inventions are directed...
by Siena Mangi | Jul 9, 2026
Since leaving the Manhattan DA’s Office’s Major Economic Crimes Bureau at the end of 2024, I am frequently asked the following question: “Is the Manhattan DA’s office (“DANY”) going to start indicting white-collar cases that the DOJ is not prioritizing? My answer has...
by Siena Mangi | Jun 25, 2026
On June 4, 2026, the U.S. Supreme Court issued a unanimous decision in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., No. 24-889, holding that generic drug manufacturer Hikma did not “actively induce” infringement of Amarin’s cardiovascular method of use...
